Johnson & Johnson Reports Positive TREMFYA® Results in Landmark Axial Psoriatic Arthritis Study
Johnson & Johnson announced positive results from a landmark clinical study evaluating TREMFYA® (guselkumab), establishing it as the first and only interleukin-23 (IL-23) inhibitor...
Jagsonpal Pharmaceuticals Acquires Wellness Portfolio of Group Pharmaceuticals Ltd. to Expand Therapeutic Footprint
Jagsonpal Pharmaceuticals Ltd. announced the successful acquisition of the Wellness portfolio of Group Pharmaceuticals Ltd., marking a strategic expansion aimed at strengthening its consumer healthcare...
FSSAI Proposes Nationwide Ban on Sale of Analogue Paneer Made from Non-Dairy Ingredients to Protect Consumers
FSSAI Notified under the draft Food Safety and Standards (Prohibition and Restrictions on Sales) Amendment Regulations, 2026, the regulatory intervention amends the principal 2011...
AbbVie Receives European Commission Approval for RINVOQ®️ in Pediatric Juvenile Idiopathic Arthritis
AbbVie announced that the European Commission has granted marketing authorization for RINVOQ® (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic...
CDSCO Issues Nationwide Advisory Against Indiscriminate Use of NSAIDs and Antibiotics to Mitigate Chronic Kidney Disease and Drug Resistance
The Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, has issued a comprehensive regulatory circular addressing the growing...
Glenmark Pharmaceuticals Receives U.S. FDA Establishment Inspection Report with VAI Status for Goa Formulations Facility
Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, announced that it has received the Establishment Inspection Report (EIR) from the United States Food and...